QualityStocks News - Ohr Pharmaceutical Appoints Two New Members to Scientific Advisory Board

Share Article

Drs. Boyer and Singerman join company’s SAB to assist in the advancement of Squalamine eye drop program

...will immensely help the company move the Squalamine eye drop program forward into its first clinical trial...

QualityStocks would like to highlight Ohr Pharmaceutical Inc., a publicly traded pharmaceutical company dedicated to the development of first-in-class drugs for under-served therapeutic needs. The company is focused on the development of novel therapeutics for the treatment of serious and unmet medical needs. Their lead compounds include OHR/AVR 118 for the treatment of Cancer Cachexia, and Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet-AMD) and other ophthalmic neovascularization disorders.

In the company’s news yesterday,

Ohr Pharmaceutical has expanded its Scientific Advisory Board (SAB) with the addition of two prominent ophthalmologists who will join the current panel of retinal ophthalmology experts focused on advancing the company’s Squalamine eye drop program into clinical efficacy trials.

David S. Boyer, M.D. of Retina-Vitreous Associates Medical Group in Los Angeles and Lawrence J. Singerman, M.D. of Retina Associates of Cleveland were appointed to Ohr Pharmaceutical’s SAB to advise the company on its clinical programs, regulatory strategy, and to provide strategic guidance to support the development of Squalamine.

“We are pleased to be working with thought leaders in the retina community of the caliber of Drs. Boyer and Singerman,” Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical stated in the press release. “Their addition to our ophthalmic SAB, together with their past experience in the clinical advancement of numerous FDA approved retinal therapeutics, including Eylea® and Lucentis®, will immensely help the company move the Squalamine eye drop program forward into its first clinical trial, which is expected to be in in the third quarter of 2012.”

Dr. Boyer is a board-certified ophthalmologist and senior partner at Retina-Vitreous Associates Medical Group. Dr. Boyer, who is also a published writer and lecturer, is a clinical professor with the University of Southern California. He has been involved in trials studying age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis.

Dr. Singerman is also a board-certified ophthalmologist and published author, and is the founder of Retina Associates of Cleveland, where he and eight other retina specialists see patients throughout Northern Ohio. Dr. Singerman is active in the field of clinical research and has been a principal investigator in more than 75 multicenter clinical trials sponsored by NIH and pharmaceutical companies.

Preclinical testing has demonstrated the Squalamine eye drop formulation as safe to ocular tissues. The formulation achieves in excess of target anti-angiogenic concentrations in the tissues of the back of the eye. In May 2012, the Squalamine eye drop program was granted Fast Track Designation by the U.S. FDA.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Editor
Visit website